The Economic Burden of Chronic Obstructive Pulmonary Disease(COPD) in South Korea
NCT ID: NCT02750189
Last Updated: 2017-07-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
390 participants
OBSERVATIONAL
2015-09-30
2017-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
This is a Multicenter, Prospective and Retrospective and Descriptive Epidemiology Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Korea
NCT01419379
Korean Chronic Obstructive Pulmonary Disease(COPD) Assessment Test Validation Study
NCT01424527
An Observational Registry of Chinese COPD Study
NCT04318912
Clinical and Economic Burden of Patients With Chronic Obstructive Pulmonary Disease in a Medicaid Population
NCT01615783
Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease and During Acute Exacerbations of the Disease, in Asia Pacific
NCT03151395
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Phase 1: Direct Cost Estimation in COPD patients (N = 400) Direct cost determined as amount of money expended to medical institutes for treatment. Estimated costs, based on the information from Health insurance review agency(HIRA) and The National Health and Nutrition Examination Survey (NHANES) data, are collected.
Phase 2: Indirect cost Estimation by Sampling Survey in COPD patient Indirect cost is extra-expanses excluding hospital fees, including cost for transportation, medical instruments, home care services and loss of labor capacity reduction. The information was collected by structured questionnaire for 12 weeks.
Phase 3: Direct/Indirect cost is validated and analyzed based on the collected information from phase 1 and 2 according to severity defined by the GOLD guideline.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mild Group
FEV₁/FVC \<70% and FEV₁≥80% direct/indirect cost
Direct cost
Money spent to treat COPD in medical institute based on HIRA
Indirect cost
extra-expanses excluding hospital fees
Moderate Group
FEV₁/FVC \<70% and 50%≤FEV₁≤80% direct/indirect cost
Direct cost
Money spent to treat COPD in medical institute based on HIRA
Indirect cost
extra-expanses excluding hospital fees
Severe Group
FEV₁/FVC \<70% and 30%≤FEV₁≤50% direct/indirect cost
Direct cost
Money spent to treat COPD in medical institute based on HIRA
Indirect cost
extra-expanses excluding hospital fees
Very Severe Group
FEV₁/FVC \<70% and FEV₁\<30% direct/indirect cost
Direct cost
Money spent to treat COPD in medical institute based on HIRA
Indirect cost
extra-expanses excluding hospital fees
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Direct cost
Money spent to treat COPD in medical institute based on HIRA
Indirect cost
extra-expanses excluding hospital fees
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* COPD patients
Exclusion Criteria
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Konkuk University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kwang-Ha Yoo
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kwang-Ha NA Yoo, Doctor
Role: PRINCIPAL_INVESTIGATOR
Konkuk University Hospial
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Konkuk University Hospital
Gwangjin Gu, Seoul, South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013 Jun 17;5:235-45. doi: 10.2147/CEOR.S34321. Print 2013.
Dang-Tan T, Ismaila A, Zhang S, Zarotsky V, Bernauer M. Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic review. BMC Res Notes. 2015 Sep 21;8:464. doi: 10.1186/s13104-015-1427-y.
Lokke A, Hilberg O, Tonnesen P, Ibsen R, Kjellberg J, Jennum P. Direct and indirect economic and health consequences of COPD in Denmark: a national register-based study: 1998-2010. BMJ Open. 2014 Jan 6;4(1):e004069. doi: 10.1136/bmjopen-2013-004069.
Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest. 2000 Feb;117(2 Suppl):5S-9S. doi: 10.1378/chest.117.2_suppl.5s.
Mannino DM, Higuchi K, Yu TC, Zhou H, Li Y, Tian H, Suh K. Economic Burden of COPD in the Presence of Comorbidities. Chest. 2015 Jul;148(1):138-150. doi: 10.1378/chest.14-2434.
Teo WS, Tan WS, Chong WF, Abisheganaden J, Lew YJ, Lim TK, Heng BH. Economic burden of chronic obstructive pulmonary disease. Respirology. 2012 Jan;17(1):120-6. doi: 10.1111/j.1440-1843.2011.02073.x.
Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006 Sep;28(3):523-32. doi: 10.1183/09031936.06.00124605. Epub 2006 Apr 12.
Kim J, Lee TJ, Kim S, Lee E. The economic burden of chronic obstructive pulmonary disease from 2004 to 2013. J Med Econ. 2016;19(2):103-10. doi: 10.3111/13696998.2015.1100114. Epub 2015 Oct 19.
Related Links
Access external resources that provide additional context or updates about the study.
Health insurance review agency in south korea
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KUH1010636
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.